Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.

The American journal of cardiology

Volumn 92, Issue 4 B, 2003, Pages 23-29

  Brewer Jr , H Bryan ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROBENZENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

BLOOD; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; REVIEW; RISK ASSESSMENT; SAFETY;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; FLUOROBENZENES; HUMANS; HYPERLIPIDEMIAS; PYRIMIDINES; RISK ASSESSMENT; SAFETY; SULFONAMIDES;

EID: 0141612021     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00779-3     Document Type: Article

References (41)